阿斯利康落地跑出“高新速度”，青岛打造外资磁吸新高地

Group 1 - The core project of AstraZeneca's inhalation aerosol production base in Qingdao has a total investment of $750 million and is expected to produce 54 million respiratory drugs annually [1][3] - The successful establishment of the project is attributed to the "high-speed" and "high-temperature" service model of Qingdao High-tech Zone, which resolved over 400 issues in a timely manner [1][3] Group 2 - Qingdao High-tech Zone has optimized its business environment, providing strong confidence and opportunities for multinational companies, as highlighted by AstraZeneca's factory manager [3] - The zone has implemented a "one-stop" service for foreign enterprises, facilitating market expansion and resource information flow through various initiatives [3][4] Group 3 - Foreign enterprises in Qingdao High-tech Zone have seen significant growth, with one company reporting a 30-fold increase in performance over ten years, supported by favorable business conditions [4] - Hexagon, a major foreign investor, has established its Greater China headquarters in the zone and recently invested over $5 million to expand its production capacity [4][5] Group 4 - The High-tech Zone has attracted 217 foreign-invested enterprises with a total investment of approximately $6.85 billion, contributing to an industrial output value of 16.573 billion yuan in 2024 [6] - The zone aims to continuously enhance its business environment and innovation resources to attract more foreign investment and promote high-quality development [6]